Genprex, Inc. (GNPX) |
| 0.2051 -0.026 (-11.33%) 10-10 16:00 |
| Open: | 0.21 |
| High: | 0.2281 |
| Low: | 0.2051 |
| Volume: | 2,900,181 |
| Market Cap: | 7(M) |
| PE Ratio: | 0.26 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.40 |
| Resistance 1: | 0.31 |
| Pivot price: | 0.20 |
| Support 1: | 0.16 |
| Support 2: | 0.13 |
| 52w High: | 3.97 |
| 52w Low: | 0.14 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Financials
| EPS | 0.850 |
| Book Value | 0.040 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -207.4 |
| Return on Equity (ttm) | -612.3 |
Company news
Fri, 12 Sep 2025
Genprex (GNPX) Files to Sell 25 Million Common Shares - GuruFocus
Tue, 02 Sep 2025
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - PR Newswire
Mon, 18 Aug 2025
Patent Protection Until 2037: Genprex Strengthens Reqorsa Cancer Therapy IP Portfolio Globally - Stock Titan
Mon, 04 Aug 2025
Genprex Achieves Major Clinical Milestones: CEO Reveals Ambitious Plans for Cancer and Diabetes Gene Therapies - Stock Titan
Mon, 23 Jun 2025
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions - PR Newswire
Mon, 09 Jun 2025
genprex regains nasdaq compliance but faces bid price challenge - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
